この製品に関するご意見・ご照会・お問合せはこちら

Hedgehog (HH) signaling pathway is a conserved pathway involved in cell growth and tissue patterning. Its abnormal signal can be found in the skin, brain, liver, prostate, breast, and other cancers and hematologic malignancies, and participate in the regulation of cell growth, migration, and invasion.

Smoothened (SMO) is a promising target for suppressing HH signaling in treating a range of malignancies, with deep pocket structures that bind effectively and selectively to drugs. SMO inhibitors can inhibit cancer formation, reduce cancer cell proliferation, trigger apoptosis, and inhibit the activity of cancer stem cells. In addition, SMO inhibitors are another strategy to combat cancer stem cells. A better understanding of the HH/SMO pathway could lead to the developing of a new class of drugs with clinical efficacy.

SMO is a member of the G protein-coupled receptor (GPCR) family and a seven-pass transmembrane protein with the N-terminal extracellular and the C-terminal intracellular. ACROBiosystems has successfully developed HEK293 expressed full-length SMO-VLP protein (Arg28-Phe787) via "FLAG" to support drugs and therapies R&D targeting SMO.

The Structure of SMO

Full-length SMO-VLP Protein (Cat. No. SMO-H52P3)

★ High identity verified by DLS

The mean peak Radius of VLP is 60-80 nm with more than 95% intensity as determined by dynamic light scattering (DLS).

★ High bioactivity verified by ELISA

Immobilized Human SMO Full Length Protein-VLP (Cat. No. SMO-H52P3) at 10 μg/mL (100 μL/well) can bind Anti-SMO antibody with a linear range of 0.01-2.5 μg/mL (QC tested).

>> Learn more about “FLAG”:

full-length multi-pass transmembrane proteins and technology platforms